| abstract |
The present invention relates to an aqueous pharmaceutical formulation comprising 1- (4 - {[4- (dimethylamino) piperidin-1-yl] carbonyl} phenyl) -3- [4- (4,6-dimorpholin-4-yl) 1,3,5-triazin-2-yl) phenyl] urea, or a pharmaceutically acceptable alkanesulfonate salt thereof, which is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient. |